$Butterfly Network(BFLY.US)The Bigger Story Is Starting to Show UpButterfly Network is best known for turning ultrasound…

$Butterfly Network(BFLY.US)

The Bigger Story Is Starting to Show Up

Butterfly Network is best known for turning ultrasound into a handheld, whole-body imaging device powered by its proprietary Ultrasound-on-Chip technology.

The problem it is solving is access. Traditional ultrasound machines can be expensive, bulky and limited to specialised departments. Butterfly’s platform is designed to make medical imaging more portable and available closer to the patient.

Its latest Q2 results suggest that the story is beginning to show up in the numbers. Revenue reached $32.6 million, up 39% year over year, driven by particularly strong US demand. Gross margin also improved to 71.4%, helped by higher-margin Butterfly Embedded licensing revenue.

This is important because Butterfly may be evolving beyond simply selling handheld scanners. Its technology can also be licensed into third-party medical devices, potentially giving the company a more scalable and profitable revenue stream.

Recent developments support that broader thesis. Butterfly expanded into Brazil, while Embedded partner Aleph Neuro demonstrated brain-imaging results using Butterfly’s chip platform.

The risks remain. Butterfly is still loss-making, cash burn matters, and strong post-earnings expectations can make the stock volatile. But compared with the June story, there is now more evidence that rising demand and Embedded licensing are beginning to strengthen both revenue growth and margins.

I’m still holding my remaining BFLY shares while watching whether this momentum continues through stronger Embedded revenue, international growth and improving profitability. The bigger Butterfly story may finally be moving from possibility to measurable progress.